IPhO is the organization whose pharmacist members are universally recognized within the pharmaceutical industry as being the most professionally equipped to contribute to the development, commercialization, promotion, and optimal use of medicines.
Talk about diversity, equity, and inclusion in the pharmaceutical industry; what should companies be doing to continue making progress?
When recruiting for clinical trials, it’s essential that the sample population accurately reflects the patients living with those disease states. Providing equitable access to medications is vital; every patient should have the same opportunity to receive the treatments they need no matter the costs. To achieve this, companies should invest in dedicated teams focused on developing solutions for patients with limited income and those in marginalized communities.
Written by Caleb Roberson, PharmD Candidate (Class of 2027) Fall 2025 IPhO Virtual Intern | Director of National Engagement, IPhO-University of Georgia College of Pharmacy Chapter
Every drug tells a story of how it travels through the body and how the body responds. Pharmacokinetics and Pharmacodynamics (PK/PD) is the science that translates that story, forming the backbone of drug development. For Doctor of Pharmacy (PharmD) students, PK/PD fellowships offer a unique opportunity to build expertise in pharmacometrics, translational pharmacology, and clinical development. These programs connect quantitative modeling with real-world applications, training fellows to turn data into strategies for dosing, formulation, trial design, and regulatory approval. (1) With clinical pharmacology playing a growing role in drug development, specialized PK/PD training is becoming an invaluable career path.
Two members of the Industry Pharmacists Organization (IPhO) National Fellows Council (NFC) Publications Committee, Izzabella Christian and Jenifer Pham, attended and presented a poster, “Analysis of 2024 PharmD Industry Fellowship Outcomes” at the 2025 ASHP Midyear Clinical Meeting.
This poster highlighted two of the outcomes that were analyzed in the corresponding publication—First Position Title and Fellow Retention. The outcomes showed that the most common First Position Title for 2024 Fellowship Alumni was "Manager" but widely varied from Associate to Director and Senior Medical Science Liaison (MSL). 62% of 2024 Fellowship Alumni were retained by their Fellowship Sponsors. These results show an overall positive outcome for Industry Fellows post-Fellowship.
